Jason Dubner Speaks with NPR about Generic Drug Price Fixing

March 7, 2018 - 45 states and the Department of Justice have alleged that generic drug manufacturers colluded to fix the price of generic medications. Thus far, two industry executives have pleaded guilty to antitrust violations. Market analysts estimate that the alleged actions may have cost U.S. businesses and consumers more than $1 billion.

Butler Rubin partner Jason Dubner spoke with NPR about the ongoing multidistrict litigation in an article titled “Probe Into Generic Drug Price Fixing Set To Widen,” which published on March 7. Dubner believes the allegations are so widespread that the alleged activity could have affected prices throughout the generic industry.

To read the full story, click here.

To read the complaint, click here.